Application of Membrane Transporters in Drug Development

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmaceutical Technology".

Deadline for manuscript submissions: closed (20 June 2024) | Viewed by 893

Special Issue Editors

School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Guangzhou 510275, China
Interests: drug transporter; pharmaceutical excipients; drug delivery; formulation development; pharmacological barriers

E-Mail Website
Guest Editor
School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China
Interests: controlled and sustained drug release; oral drug delivery systems; biopharmaceutics; pharmacokinetics; drug transporters

Special Issue Information

Dear Colleagues,

More than 400 membrane transporters in two major superfamilies—ATP-binding cassette (ABC) and solute carrier (SLC)—have been discovered in the human genome and are widely expressed throughout the body. Numerous studies have demonstrated that these transporters play key roles in the absorption, distribution, metabolism and excretion (ADME) properties of drug substances, altering their therapeutic and adverse effects. Additionally, drug–drug interactions (DDIs) are observed due to their transporter-related features, triggering follow-up clinical studies. Thus, a comprehensive understanding of the interactions between transporters and drugs can lead to breakthroughs in the discovery and development of new molecules.

This Special Issue attempts to highlight the latest advances in the application of transporter information in drug discovery and development. We are pleased to invite you to contribute your original research or review articles on the following areas: mechanisms on the variability of transporters caused by genetic, epigenetic and other factors, innovative methods for studying and predicting drug–transporter interactions and the design of transporter-mediated drugs.

Dr. Mai Yang
Prof. Dr. Zheng Cai
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • membrane transporters
  • ABC
  • SLC
  • transporter-mediated drug
  • drug–drug interaction
  • drug development
  • pharmacological barriers

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

18 pages, 5523 KiB  
Article
Evidence for the Role of the Mitochondrial ABC Transporter MDL1 in the Uptake of Clozapine and Related Molecules into the Yeast Saccharomyces cerevisiae
by Chrispian W. Theron, J. Enrique Salcedo-Sora, Justine M. Grixti, Iben Møller-Hansen, Irina Borodina and Douglas B. Kell
Pharmaceuticals 2024, 17(7), 938; https://doi.org/10.3390/ph17070938 (registering DOI) - 13 Jul 2024
Viewed by 255
Abstract
Clozapine is an antipsychotic drug whose accumulation in white cells can sometimes prove toxic; understanding the transporters and alleles responsible is thus highly desirable. We used a strategy in which a yeast (Saccharomyces cerevisiae) CRISPR-Cas9 knock-out library was exposed to cytotoxic [...] Read more.
Clozapine is an antipsychotic drug whose accumulation in white cells can sometimes prove toxic; understanding the transporters and alleles responsible is thus highly desirable. We used a strategy in which a yeast (Saccharomyces cerevisiae) CRISPR-Cas9 knock-out library was exposed to cytotoxic concentrations of clozapine to determine those transporters whose absence made it more resistant; we also recognised the structural similarity of the fluorescent dye safranin O (also known as safranin T) to clozapine, allowing it to be used as a surrogate marker. Strains lacking the mitochondrial ABC transporter MDL1 (encoded by YLR188W) showed substantial resistance to clozapine. MDL1 overexpression also conferred extra sensitivity to clozapine and admitted a massive increase in the cellular and mitochondrial uptake of safranin O, as determined using flow cytometry and microscopically. Yeast lacking mitochondria showed no such unusual accumulation. Mitochondrial MDL1 is thus the main means of accumulation of clozapine in S. cerevisiae. The closest human homologue of S. cerevisiae MDL1 is ABCB10. Full article
(This article belongs to the Special Issue Application of Membrane Transporters in Drug Development)
Show Figures

Figure 1

Back to TopTop